Kenyan Company Receives WHO Prequalification for Generic Antiretroviral
November 3, 2011
"The cost of HIV/AIDS medicine is expected to drop by 30 percent in Kenya, enabling more people to access life-prolonging drugs, after the World Health Organization (WHO) gave the green light to a local company manufacturing generics, The Star newspaper reported on Wednesday," AlertNet reports. Universal Corporation received WHO prequalification status for its generic combination antiretroviral Lamozido, which "will enable the company to bid for international tenders to supply drugs to governments and non-governmental organizations, who in turn give them to people living with HIV/AIDS," the news service writes (Migiro, 11/2).
South African Public Health Experts Urge Countries to Use TRIPS to Produce Generic Drugs, IPS Reports
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)